<DOC>
	<DOCNO>NCT01313208</DOCNO>
	<brief_summary>This study design evaluate effectiveness add etanercept disease modify anti-rheumatic drug ( DMARD ) therapy patient moderately active Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>Moderate Rheumatoid Arthritis ( RA ) With Etanercept ( Enbrel )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Male female ≥18 ≤80 year age time screen Diagnosed rheumatoid arthritis determine meeting 1987 American College Rheumatology ( ACR ) classification criterion rheumatoid arthritis least 6 month Moderate rheumatoid arthritis screening , define disease activity score ( 28 joint ) calculate use Creactive protein formula ( DAS28CRP ) &gt; 3.2 ≤ 5.1 Active rheumatoid arthritis define ≥ 3 swollen joint ( 28 joint examine ) ≥ 3 tender/painful joint ( 28 joint examine ) screen baseline . ( A full 66/68 count joint count perform baseline , joint 28count joint count consider eligibility . The 28joint count consist finger joint exclude distal interphalangeal joint , wrist , elbow , shoulder , knee ) Must currently take DMARD methotrexate , sulfasalazine , leflunomide , minocycline , and/or hydroxychloroquine Prosthetic joint infection within 5 year screen native joint infection within 1 year screen Class IV rheumatoid arthritis accord ACR revise response criterion Any active infection ( include chronic localized infection ) antiinfectives indicate within 28 day prior first investigational product dose Previously use one experimental biologic DMARD . Patient prior use one experimental biologic permit subject receive 8 week treatment . The use experimental biologic must occur within 2 month first dose investigational product Previously use one commercially available biologic DMARD . Subject prior use one commercially available biologic permit patient receive 8 week treatment discontinue lack effect . The use biologic must occur within 2 month first dose investigational product . Acceptable prior use biologics include follow example : No 4 injection adalimumab No 8 ( 50 mg ) injection etanercept No 2 infusion infliximab No 2 infusion abatacept Additional inclusion ( exclusion ) criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RA</keyword>
	<keyword>Enbrel</keyword>
	<keyword>DMARD</keyword>
	<keyword>Joint Count</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>disease modify anti-rheumatic drug</keyword>
</DOC>